Cancer chemotherapy administered by activated carbon particles and liposomes.
In cancer chemotherapy, a specific drug delivery system is expected since many anticancer drugs show toxicity against not only cancer cells but also against normal tissues. The dosage form comprising anticancer drugs adsorbed on activated carbon particles or encapsulated in liposomes is developed as a drug-delivery system which enhances the therapeutic efficacy and reduces the adverse effects. The dosage forms are versatile in size and electric charge, so that large amounts of the drugs are distributed to the "targeted" organs or tissues and lesser amounts are distributed to the whole body. The dosage forms are designed to release the drugs slowly for a long time at local sites. Through this process, practical use of the dosage forms as an anticancer drug carrier results in an enhancement of anticancer efficacy on the local lesion and a decrease of systemic toxicity.
Hagiwara
A
A
1st Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Takahashi
T
T
Oku
N
N
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000287:Administration, Topical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001685:Biological Factors / Q000008:administration & dosage; D002244:Carbon; D016207:Cytokines; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes / Q000032:analysis; D008207:Lymphatic Metastasis; D008264:Macrophages / Q000187:drug effects; D009000:Monocytes / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001685:Biological Factors; D016207:Cytokines; D004337:Drug Carriers; D008081:Liposomes; D002244:Carbon